

2025 OPA Annual Conference Learning Objectives

Friday, April 11

ACPE #0129-0000-25-013-L04-P

0.1 CEU

Note: Live Only

Preceptor Training/ Development: Launching of a New APPE evaluation across all colleges; mirroring the new ACPE 2026 standards at your practice site

Tonya Brim PharmD, CDCES, BCGP, Megan Kaun, R.Ph., PharmD, Julie E. Legg, PharmD, FNAP, and Michael B Doherty, PharmD

At the completion of this activity, the participant will be able to:

1. review the new ACPE standards as it relates to experiential learning;
2. review the identified core learning objectives and activities and how this relates to your practice site;
3. develop an approach to student evaluation process including summative and formative feedback; and
4. apply the new APPE learning objectives to your practice area.

ACPE #0129-0000-25-014-L05-P/T

0.1 CEU

ACPE #0129-0000-25-014-H05-P/T

0.1 CEU

Out of Sight Out of Mind: Medication Safety Practices in the Outpatient Pharmacy Setting

Kembral Nelson, PharmD, MS, BCSCP, CMQOE & Aneeka Kittaneh, PharmD

At the completion of this activity, the participant will be able to:

1. explain the importance of increased visibility and communication of medication safety efforts in the outpatient pharmacy setting;
2. name strategies to utilize for establishing medication presence in the outpatient pharmacy setting;
3. describe a process to increase awareness of safety trends, best practices, and initiatives amongst outpatient pharmacy staff and leadership; and
4. discuss the benefits of a Risk and Control Matrix tool as a strategic method for medication safety initiatives.

ACPE #0129-0000-25-015-L01-P/T

0.1 CEU

ACPE #0129-0000-25-015-H01-P/T

0.1 CEU

Updates in Diabetes Technology

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP

At the completion of this activity, the participant will be able to:

1. describe the different CGM and insulin pump options for people with type 1 and type 2 diabetes;
2. discuss how AI tools are being used for medication dosing and meal planning in diabetes; and
3. identify optimal candidates for these new technologies.

ACPE #0129-0000-25-041-L01-P/T 0.1 CEU

ACPE #0129-0000-25-041-H01-P/T 0.1 CEU

Seamless Transitions: Pharmacist-Led Conversion from VKAs to DOACs

Rachel Wells, PharmD, RPh

At the completion of this activity, the participant will be able to:

1. summarize the latest research findings that support the safety and efficacy of Vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) conversions;
2. explain the clinical benefits of transitioning patients from VKAs to DOACs; and
3. outline practical strategies and tools for pharmacists to effectively implement VKA to DOAC conversions in clinical practice.

ACPE #0129-0000-25-016-L04-P/T 0.15 CEU **Note: Live Only**

2025 Ohio Innovative Practice Forum

Jennifer Rodis, PharmD, FAPhA

At the completion of this activity, the participant will be able to:

1. describe innovative pharmacy practice models in Ohio;
2. explain how individual pharmacy practices and practitioners are expanding patient care services;
3. describe the successes and challenges of these programs including their financial viability and impact on outcome measures; and
4. apply these ideas, opportunities, and resources to enhance his/her own pharmacy practice.

ACPE #0129-0000-25-017-L06-P/T 0.15 CEU

ACPE #0129-0000-25-017-H06-P/T 0.15 CEU

2025 Spring Immunization Update

Olivia Kinney, PharmD, MS

At the completion of this activity, the participant will be able to:

1. identify changes in vaccine guidance since the February ACIP Meeting outcome;
2. recommend appropriate vaccines for patients using updated guidance; and
3. discuss the future landscape of vaccines.

ACPE #0129-0000-25-042-L04-P 0.1 CEU

ACPE #0129-0000-25-042-H04-P 0.1 CEU

A Decent Recommendation: Crafting Valuable Letters of Recommendation for Pharmacy Residency Candidates

Casey May, PharmD, BCCCP, FNCS & Zach Woods, PharmD, BCACP

At the completion of this activity, the participant will be able to:

1. explain how letters of recommendation have evolved and the utilization of letters of recommendation within the residency application process;
2. recognize evidence behind letter writing and pharmacy residency candidates' application scores and clinical aptitude; and
3. apply recommendations to constructing more valuable letters of recommendation for pharmacy residency candidates.

ACPE #0129-0000-25-043-L07-P/T 0.1 CEU

ACPE #0129-0000-25-043-H07-P/T 0.1 CEU

USP 795 Essentials: Integrating Standards into Daily Practice

Jerra Banwarth, RPh., FACP

At the completion of this activity, the participant will be able to:

1. identify USP Standards that require significant time to implement and maintain;
2. discuss which USP 795 requirements can be implemented the most efficiently; and
3. describe how to implement standards into your workflow.

ACPE #0129-0000-25-019-L01-P/T 0.15 CEU **Note: Live Only**

2025 OTC Challenge

Max Conrad, PharmD & Emma Siegel, PharmD

At the completion of this activity, the participant will be able to:

1. identify and explain aspects of the effective and safe practice of pharmacy self-care treatments;
2. describe at least two over the counter and prescription medication interactions that pharmacists and pharmacy technicians should be aware of;
3. list three OTC medications and their use. Pharmacists should identify counseling points for each of three OTC medications; and
4. identify and explain aspects of the effective and safe practice of pharmacy self-care treatments.

ACPE #0129-0000-25-020-L04-P/T 0.15 CEU

ACPE #0129-0000-25-020-H04-P/T 0.15 CEU

Living with Your Eyes Open: The Damaging Effects of Self-Deception

Bruce Berger, PhD

At the completion of this activity, the participant will be able to:

1. identify the causes of self-deception;
2. distinguish between treating people like objects and treating people like people; and
3. recognize how to take steps to be self-deceived less often.

ACPE #0129-0000-25-021-L04-P/T 0.15 CEU

ACPE #0129-0000-25-021-H04-P/T 0.15 CEU

Inclusive Practice in Focus: The Pharmacist's Role in Gender-Affirming Care

Shreya Barde, PharmD; Grace Havens, R.Ph., PharmD; & Teagan Vaughn, PharmD, RPh, AAHIVP

At the completion of this activity, the participant will be able to:

1. review pharmacotherapy options and management strategies for gender-affirming care;
2. discuss potential barriers for patient access to gender-affirming care;
3. identify the pharmacist's role in facilitating access to gender-affirming care; and
4. discuss best practices for creating an inclusive and equitable environment for gender-diverse patients.

ACPE #0129-0000-25-022-L01-P/T 0.15 CEU

ACPE #0129-0000-25-022-H01-P/T 0.15 CEU

Hit Me with Your Best Shot: Use of Incretin Mimetics for Weight Management

Emily Vrontos, PharmD, CDE

At the completion of this activity, the participant will be able to:

1. explain obesity as a medical diagnosis, including co-morbid conditions and health outcomes;
2. compare the efficacy and dosing of incretin mimetics; and
3. identify appropriate patients to start on incretin mimetics, screening for contraindications and reviewing concurrent drug therapy.

ACPE #0129-0000-25-023-L03-P/T 0.1 CEU

ACPE #0129-0000-25-023-H03-P/T 0.1 CEU

Ohio Pharmacy Laws and Rules and How They Affect Practicing Pharmacists

Donnie Sullivan, R.Ph., PhD

At the completion of this activity, the participant will be able to:

1. describe the pharmacy continuous quality improvement program for dispensing errors;
2. describe outpatient minimum standards and how they affect practicing pharmacists; and
3. describe commonly misunderstand Ohio pharmacy laws and how they affect practice.

ACPE #0129-0000-25-024-L04-P/T

0.1 CEU

Note: Live Only

2025 Ohio Research Forum

Aleda Chen, PharmD, PhD, FAPhA

At the completion of this activity, the participant will be able to:

1. describe research projects being conducted by pharmacists, student pharmacists and faculty in Ohio; and
2. describe the impact these research projects have on the practice of pharmacy, economic/social/administrative areas within the profession and/or pharmacy education.

ACPE #0129-0000-25-025-L01-P

0.1 CEU

ACPE #0129-0000-25-025-H01-P

0.1 CEU

Chronic Kidney Disease: A Systems of Excellence Committee in Primary Care

Erica Reinhardt, PharmD

At the completion of this activity, the participant will be able to:

1. identify how to screen patients for chronic kidney disease in the Primary Care Setting;
2. demonstrate how to optimize pharmacotherapy (RAAS and SGLT2i); and
3. discuss when to refer to nephrology.

Saturday, April 12

ACPE #0129-0000-25-026-L03-P/T

0.1 CEU

ACPE #0129-0000-25-026-H03-P/T

0.1 CEU

2025 Spring Law Update

Sheri Zapadka R.Ph., PharmD

At the completion of this activity, the participant will be able to:

1. review recent changes and additions to Chapter 4729 of the Ohio Administrative Code;
2. explore common rule misconceptions and violations; and
3. discuss investigative cases and board actions.

ACPE #0129-0000-25-044-L01-P

0.1 CEU

ACPE #0129-0000-25-044-H01-P

0.1 CEU

Breathing New Life into Asthma Care: A Pharmacist's Role in Managing Respiratory Health *Regann Rutschilling, PharmD, AE-C*

At the completion of this activity, the participant will be able to:

1. define the pathophysiology and key symptoms of asthma;
2. identify criteria on spirometry indicative of a diagnosis of asthma; and
3. develop starting therapy recommendations for patients ages 12 and up with asthma.

ACPE #0129-0000-25-018-L04-P/T 0.1 CEU

ACPE #0129-0000-25-018-H04-P/T 0.1 CEU

Leveling the Playing Field: Reducing Interview Bias and Variability

Benjamin King, PharmD, BCACP

At the completion of this activity, the participant will be able to:

1. define interviewer bias and inter- and intrarater variability;
2. demonstrate techniques to minimize the impact of common interviewer biases;
3. recommend strategies to improve rater reliability; and
4. develop a structured interview process that reduces subjectivity.

ACPE #0129-0000-25-027-L04-P/T 0.15 CEU

ACPE #0129-0000-25-027-H04-P/T 0.15 CEU

2025 Legislative Update

Michelle Fitzgibbon; David Burke, R.Ph., MBA; & E. Michael Murphy, PharmD, MBA

At the completion of this activity, the participant will be able to:

1. discuss current legislative and policy changes at both the state and federal level that will impact the practice of pharmacy;
2. explain how to effectively advocate for OPA supported legislative changes with state legislators and federal elected officials; and
3. identify issues on OPA's legislative agenda for 2024-25 and what they may mean for pharmacy practice.

ACPE #0129-0000-25-028-L04-P/T 0.15 CEU

ACPE #0129-0000-25-028-H04-P/T 0.15 CEU

Technology, Innovation and Pharmacy: New Beginnings

Marc A. Sweeney, PharmD, BCMA; Julie A. Murphy, PharmD, FASHP, FCCP, BCPS; Loulwa Maktabi, PharmD, BCPS; & Chris Antypas, PharmD

At the completion of this activity, the participant will be able to:

1. describe evolving technologies that will impact the next generation of pharmacists;
2. discuss how technology can improve patient care for pharmacists;
3. identify challenges in pharmacy practice that can be solved by advancing technology ; and
4. describe new innovations that intersect with pharmacy practice.

ACPE #0129-0000-25-029-L04-P/T

0.15 CEU

Note: Live Only

Question, Persuade, Refer (QPR) - Suicide Prevention

Austin Lucas, B.S.

At the completion of this activity, the participant will be able to:

1. discuss why pharmacists are in a unique position to become trained in suicide prevention as a provider of various medications, as well as identifying colleagues at-risk;
2. identify various lethal means patients might use when at-risk for suicide; and
3. explain how to navigate a conversation with someone identified at an elevated suicide risk with a focus on lethal means safety.

ACPE #0129-0000-25-030-L01-P/T

0.15 CEU

ACPE #0129-0000-25-030-H01-P/T

0.15 CEU

Lipid Labyrinth: Unblocking Pathways with Fresh Cholesterol Management Guidelines

Jennifer Huang, PharmD; Anna Packis, PharmD; and Maryn N. Horn, PharmD, R.Ph.

At the completion of this activity, the participant will be able to:

1. summarize the treatment recommendations from the 2018 ACC/AHA and 2021 and 2022 ACC Expert Consensus Decision Pathway on hypercholesterolemia management;
2. discuss the 2025 AACE Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia;
3. identify lipid management strategies for older adults per guidelines; and
4. evaluate the challenges in applying the updated guidelines and recent clinical trials for treating hypercholesterolemia in special populations, including older adults.

ACPE #0129-0000-25-031-L05-P/T

0.1 CEU

ACPE #0129-0000-25-031-H05-P/T

0.1 CEU

Root of the Problem: Implementing Root Cause Analysis and Just Culture in an Outpatient Setting

Jennifer Wick PharmD, MPH, BCACP

At the completion of this activity, the participant will be able to:

1. summarize Just Culture, Root Cause Analysis (RCA), and their importance to Medication Safety;
2. compare and contrast common strategies for implementing Just Culture and RCA in healthcare; and
3. design an RCA and subsequent safety plan for a mock outpatient healthcare system.

ACPE #0129-0000-25-032-L01-P/T 0.1 CEU

ACPE #0129-0000-25-032-H01-P/T 0.1 CEU

A Functional Medicine Approach to Perimenopause

Amy Sapola, PharmD, RPh, FAIHM, IFMCP, RYT-200, NBC-HWC

At the completion of this activity, the participant will be able to:

1. evaluate which patients are appropriate for MHT;
2. describe the benefits of menopausal hormone therapy for a perimenopausal women;
3. explain the role of progesterone;
4. Describe the role of diet and lifestyle; and
5. identify relevant labs and how to utilize them to guide care.

ACPE #0129-0000-25-045-L04-P/T 0.1 CEU

ACPE #0129-0000-25-045-H04-P/T 0.1 CEU

Breaking the Mold: Advanced Roles for Pharmacy Technicians

Briana Wukovich, CPhT-Adv, CSPT; Brooke Powell, CPhT; Adrean Jones, BS, CPhT; Emily Burke, CPhT-Adv; and Noriliz Sayachak, CPhT

At the completion of this activity, the participant will be able to:

1. describe the career pathways and opportunities that led panelists to leadership and non-traditional advanced roles in pharmacy practice;
2. identify key skills and strategies that pharmacy technicians can use to pursue advanced roles in Pharmacy; and
3. discuss the evolving scope of pharmacy technician responsibilities and how to advocate for professional growth within the field.

ACPE #0129-0000-25-046-L04-P/T 0.1 CEU

ACPE #0129-0000-25-046-H04-P/T 0.1 CEU

Maternal Health Matters: Pharmacy's Role in Addressing Care Deserts Across Ohio

Myriam Shaw Ojeda, PharmD, MPH & Natalie DiPietro Mager, PharmD, PhD, MPH

At the completion of this activity, the participant will be able to:

1. describe patient and community-level maternal health indicators across Ohio;
2. explain the potential impact of pharmacy services on improving maternal health; and

- list practical opportunities for pharmacist-led services to support maternal health in Ohio.

ACPE #0129-0000-25-033-L07-P/T 0.1 CEU

ACPE #0129-0000-25-033-H07-P/T 0.1 CEU

Effective Oversight in Sterile Compounding: Ensuring Quality and Safety

Jacob Deitsch, Pharm.D., BCPS, BCSCP, HDDP, IgCP

At the completion of this activity, the participant will be able to:

- list the requirements for training and competency, cleanroom environmental control, and standard operating procedures according to USP Chapter <797>;
- describe the consequences of losing the state of control within sterile compounding operations; and
- develop a CAPA (Corrective Action Preventative Action) plan to remedy the situation and learn how to prevent it from occurring in the future.

ACPE #0129-0000-25-034-L01-P/T 0.1 CEU

ACPE #0129-0000-25-034-H01-P/T 0.1 CEU

Cosmetic Science Recent Updates

Hannah (Culyer) Pangallo, PharmD

At the completion of this activity, the participant will be able to:

- discuss the latest trends and breakthroughs in cosmetic science; and
- explain how recent advancements in cosmetic science are relevant to the pharmacy profession.

Sunday, April 13

ACPE #0129-0000-25-035-L01-P/T 0.1 CEU

ACPE #0129-0000-25-035-H01-P/T 0.1 CEU

New Drug Update 2025: CV, Respiratory, GI, ID, Renal

Karen Kier, PhD, M.Sc., R.Ph.

At the completion of this activity, the participant will be able to:

- review the pharmacology and therapeutics of selected prescription medications released to the market within the past year;

2. state the indications and clinical applications of the medications presented, and how they compare to current therapies;
3. list the most common adverse effects, toxicities, and significant drug-drug and drug-food interactions reported; and
4. explain important patient/caregiver counseling information for these medications.

ACPE #0129-0000-25-036-L03-P/T 0.1 CEU

ACPE #0129-0000-25-036-H03-P/T 0.1 CEU

Rx to OTC: A Regulatory Analysis of Access and Cost Implications After Drugs Make the Switch

Bella Blankenship, PharmD, R.Ph.

At the completion of this activity, the participant will be able to:

1. recognize the significant historical events in United States drug regulation that have shaped the current regulatory landscape of these issues;
2. identify the criteria needed for the United States Food and Drug Administration (USFDA) to approve a prescription medication for nonprescription use;
3. recognize the implications on medication cost and access that have resulted from the prescription to nonprescription approval of medications in the past twenty years; and
4. list implications on cost and access for future prescription to nonprescription medication approvals.

ACPE #0129-0000-25-037-L01-P/T 0.1 CEU

ACPE #0129-0000-25-037-H01-P/T 0.1 CEU

New Drug Update 2025: CNS, Behavioral Health, Musculoskeletal, Immunology, Oncology, Ocular

Karen Kier, PhD, M.Sc., R.Ph.

At the completion of this activity, the participant will be able to:

1. review the pharmacology and therapeutics of selected prescription medications released to the market within the past year;
2. state the indications and clinical applications of the medications presented, and how they compare to current therapies;
3. list the most common adverse effects, toxicities, and significant drug-drug and drug-food interactions reported; and
4. explain important patient/caregiver counseling information for these medications.

ACPE #0129-0000-25-038-L01-P/T 0.1 CEU

ACPE #0129-0000-25-038-H01-P/T 0.1 CEU

Heart of the Matter: Impact of Social Determinants on Cardiovascular Disease

Nira Kadakia, PharmD, BCACP

At the completion of this activity, the participant will be able to:

1. describe social determinants and how they affect cardiovascular disease prevalence, management, and outcomes; and
2. apply different strategies to address SDOH concerns and improve outcomes for a patient with cardiovascular disease.

ACPE #0129-0000-25-039-L01-P/T 0.1 CEU

ACPE #0129-0000-25-039-H01-P/T 0.1 CEU

Be Prepared! A Guide to Outpatient Medication Management During Natural Disasters

Allison A Butler, PharmD & Lena Abdul-Aziz, PharmD, RPh

At the completion of this activity, the participant will be able to:

1. assess patient needs: participants will be able to evaluate the unique medication needs of patients during natural disasters, including understanding chronic conditions, identifying essential medications, and recognizing the importance of medication adherence in emergency situations;
2. employ strategies for medication access: participants will be able to develop and implement effective strategies to ensure patients have access to their necessary medications during disasters, including creating emergency supply kits, coordinating with pharmacies, and exploring options for medication refills in disrupted environments; and
3. demonstrate how to educate patients on preparedness: participants will be able to effectively educate patients on the importance of medication preparedness, including how to maintain an updated medication list, the significance of knowing potential alternatives for critical medications, and the steps to take if they encounter medication shortages during emergencies.

ACPE #0129-0000-25-040-L01-P/T 0.1 CEU

ACPE #0129-0000-25-040-H01-P/T 0.1 CEU

Healthy at Home Virtual Clinic: An Innovative Approach to Reduce Readmission Rates

Korie Payne, PharmD

At the completion of this activity, the participant will be able to:

1. review Guideline Directed Medical Therapy (GDMT) for heart failure;
2. explain how our Healthy at Home Virtual Clinic has benefited our heart failure patients and help to reduce readmission rates;
3. discuss findings of small study conducted within the clinic for our heart failure patients; and
4. evaluate the benefits of having a pharmacist involved within the clinic.